Viridian Therapeutics target price raised to $42 from $39 by Truist Securities
VRDN•Truist Securities raised its target price on Viridian Therapeutics to $42 from $39.
Related News
DOF secures Petrobras contract extension for Skandi Olinda through January 2028
PBR•
AI sharpens cat-and-mouse hacking battle as companies strengthen defences
XLK•
B2Gold cites Fekola impairment reversal as driver of Q3 2026 earnings rise
BTG•
United Therapeutics: Raymond James raises target price to $720 from $717
UTHR•
Greif Inc: Baird raises target price to $80 from $75
GEF•